ReviewFrontiers in psychiatry2017
The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.
Review in Frontiers in psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Molecular psychiatry · 2025Pooled it
- Uncovering transcriptomic biomarkers for enhanced diagnosis of methamphetamine use disorder: a comprehensive review.Frontiers in psychiatry · 2023Pooled it
- On Perception and Consciousness in HPPD: A Systematic Review.Frontiers in neuroscience · 2021Pooled it
- Visual Snow Syndrome as a Network Disorder: A Systematic Review.Frontiers in neurology · 2021Pooled it
- DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish.Molecules (Basel, Switzerland) · 2026Article
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.Current issues in molecular biology · 2026Review
- Hallucinogen Persisting Perception Disorder in a Young Adult Case Report.Case reports in psychiatry · 2026Article
- Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review.Harvard review of psychiatry · 2025Article
- Review
- Psychological effects of psychedelics in adolescents.Frontiers in child and adolescent psychiatry · 2024Article
- Review
- Article
- Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample.Frontiers in psychiatry · 2023Article
- Psilocybin for Depression: From Credibility to Feasibility, What's Missing?Pharmaceuticals (Basel, Switzerland) · 2022Article
- Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.Addictive behaviors reports · 2022Article
- Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology.Journal of neurology · 2022Article
- Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.Psychopharmacology · 2022Article
- Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.Journal of clinical medicine · 2022Article
- Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.Frontiers in pharmacology · 2022Review
- Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases of HPPD. Symptomatology mainly comprises visual disorders (i.e., geometric pseudo-hallucinations, haloes, flashes of colors/lights, motion-perception deficits, afterimages, micropsia, more acute awareness of floaters, etc.), even though depressive symptoms and thought disorders may be comorbidly present. Although HPPD was first described in 1954, it was just established as a fully syndrome in 2000, with the revised fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). HPPD neural substrates, risk factors, and aetiopathogenesys still largely remain unknown and under investigation, and many questions about its pharmacological targets remain unanswered too. A critical mini review on psychopathological bases, etiological hypothesis, and psychopharmacological approaches toward HPPD, including the association with some novel substances, are provided here, by means of a literature search on PubMed/Medline, Google Scholar, and Scopus databases without time restrictions, by using a specific set of keywords. Pharmacological and clinical issues are considered, and practical psychopharmacological recommendations and clinical guidelines are suggested.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.